High expression of APOBEC3G predicts unfavorable prognosis and immune infiltration in patients with acute myeloid leukemia
Authors: 
Fengjiao Chang, Jinhang Hu, Jie Lin, Fang LiuAuthors Info & Claims
Fengjiao Chang, Jinhang Hu, Jie Lin, Fang LiuAuthors Info & ClaimsPages 128 - 135
Abstract
The potential clinical benefits of immunotherapy against acute myeloid leukemia (AML) have been suggested recently. Thus, identifying the molecular mechanisms underlying immune surveillance evasion is critical. The APOBEC family (apolipoprotein B mRNA editing catalytic subunit) is involved in multiple tumorigenesis, and might be predictive biomarkers for the immunotherapy response. However, the role of APOBEC3 genes and their association with prognosis and immune response in AML have not been investigated. In this study, by extracting the RNA sequence data and clinical characteristics of AML from The Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) datasets, and Genotype-Tissue Expression (GTEx) project, we found that the expression of APOBEC3G was significantly upregulated, and high expression of APOBEC3G was an independent prognostic factor in AML. Moreover, APOBEC3G was highly expressed in non-M3 AML patients, intermediate and poor cytogenetic risk groups, patients with wild-type NPM1 and above 60 years old. In addition, APOBEC3G was strongly correlated with immune regulation, immune cells infiltration and immune checkpoint inhibitors expression, which might be associated with immune escape of AML cells. Our findings suggest the potential impact of APOBEC3G on prognosis and immunotherapies against AML.
References
[1]
A. Khwaja, M. Bjorkholm, R.E. Gale, R.L. Levine, C.T. Jordan, G. Ehninger, C.D. Bloomfield, E. Estey, A. Burnett, J.J. Cornelissen, D.A. Scheinberg, D. Bouscary, D.C. Linch, Acute myeloid leukaemia, Nat Rev Dis Primers 2 (2016) 16010.
[2]
S. Jaramillo, R.F. Schlenk, Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question, Haematologica 108(2) (2023) 342-352.
[3]
H. Dohner, A.H. Wei, B. Lowenberg, Towards precision medicine for AML, Nat Rev Clin Oncol 18(9) (2021) 577-590.
[4]
E.A. Tawfik, N.A. Aldrak, S.H. Albrahim, D.A. Alzahrani, H.A. Alfassam, S.M. Alkoblan, A.M. Almalik, K.S. Chen, R. Abou-Khalil, K. Shah, N.M. Zaidan, Immunotherapy in hematological malignancies: recent advances and open questions, Immunotherapy 13(14) (2021) 1215-1229.
[5]
S. Stavrou, S.R. Ross, APOBEC3 Proteins in Viral Immunity, J Immunol 195(10) (2015) 4565-70.
[6]
S. Venkatesan, M. Angelova, C. Puttick, H. Zhai, D.R. Caswell, W.T. Lu, M. Dietzen, P. Galanos, K. Evangelou, R. Bellelli, E.L. Lim, T.B.K. Watkins, A. Rowan, V.H. Teixeira, Y. Zhao, H. Chen, B. Ngo, L.P. Zalmas, M. Al Bakir, S. Hobor, E. Gronroos, A. Pennycuick, E. Nigro, B.B. Campbell, W.L. Brown, A.U. Akarca, T. Marafioti, M.Y. Wu, M. Howell, S.J. Boulton, C. Bertoli, T.R. Fenton, R.A.M. de Bruin, A. Maya-Mendoza, E. Santoni-Rugiu, R.E. Hynds, V.G. Gorgoulis, M. Jamal-Hanjani, N. McGranahan, R.S. Harris, S.M. Janes, J. Bartkova, S.F. Bakhoum, J. Bartek, N. Kanu, C. Swanton, T.R. Consortium, Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution, Cancer Discov 11(10) (2021) 2456-2473.
[7]
S. Wang, M. Jia, Z. He, X.S. Liu, APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer, Oncogene 37(29) (2018) 3924-3936.
[8]
T. Peng, B. Liu, S. Lin, C. Cao, P. Wu, W. Zhi, Y. Wei, T. Chu, L. Gui, W. Ding, APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma, Heliyon 8(12) (2022) e12191.
[9]
B. Ru, C.N. Wong, Y. Tong, J.Y. Zhong, S.S.W. Zhong, W.C. Wu, K.C. Chu, C.Y. Wong, C.Y. Lau, I. Chen, N.W. Chan, J. Zhang, TISIDB: an integrated repository portal for tumor-immune system interactions, Bioinformatics 35(20) (2019) 4200-4202.
[10]
Z. Cai, J. Wei, Z. Chen, H. Wang, High ROBO3 expression predicts poor survival in non-M3 acute myeloid leukemia, Exp Biol Med (Maywood) 246(10) (2021) 1184-1197.
[11]
O. Dufva, P. Polonen, O. Bruck, M.A.I. Keranen, J. Klievink, J. Mehtonen, J. Huuhtanen, A. Kumar, D. Malani, S. Siitonen, M. Kankainen, B. Ghimire, J. Lahtela, P. Mattila, M. Vaha-Koskela, K. Wennerberg, K. Granberg, S.K. Leivonen, L. Meriranta, C. Heckman, S. Leppa, M. Nykter, O. Lohi, M. Heinaniemi, S. Mustjoki, Immunogenomic Landscape of Hematological Malignancies, Cancer Cell 38(3) (2020) 424-428.
[12]
A.M. Green, K. Budagyan, K.E. Hayer, M.A. Reed, M.R. Savani, G.B. Wertheim, M.D. Weitzman, Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint, Cancer Res 77(17) (2017) 4579-4588.
[13]
Z. Wang, H. Yan, J.C. Boysen, C.R. Secreto, R.C. Tschumper, D. Ali, Q. Guo, J. Zhong, J. Zhou, H. Gan, C. Yu, D.F. Jelinek, S.L. Slager, S.A. Parikh, E. Braggio, N.E. Kay, B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells, Blood Cancer J 12(7) (2022) 99.
[14]
B.A. Walker, C.P. Wardell, A. Murison, E.M. Boyle, D.B. Begum, N.M. Dahir, P.Z. Proszek, L. Melchor, C. Pawlyn, M.F. Kaiser, D.C. Johnson, Y.W. Qiang, J.R. Jones, D.A. Cairns, W.M. Gregory, R.G. Owen, G. Cook, M.T. Drayson, G.H. Jackson, F.E. Davies, G.J. Morgan, APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma, Nat Commun 6 (2015) 6997.
[15]
T. Haferlach, A. Kohlmann, S. Schnittger, M. Dugas, W. Hiddemann, W. Kern, C. Schoch, AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes, Genes Chromosomes Cancer 43(2) (2005) 113-27.
[16]
B. Falini, S. Sciabolacci, L. Falini, L. Brunetti, M.P. Martelli, Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field, Leukemia 35(11) (2021) 3113-3126.
[17]
N.R. Neuendorff, T. Burmeister, B. Dorken, J. Westermann, BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features, Ann Hematol 95(8) (2016) 1211-21.
[18]
Q. Qiu, F. Chi, D. Zhou, Z. Xie, Y. Liu, H. Wu, Z. Yin, W. Shi, H. Qian, Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers, J Med Chem (2023).
[19]
H.A. Knaus, S. Berglund, H. Hackl, A.L. Blackford, J.F. Zeidner, R. Montiel-Esparza, R. Mukhopadhyay, K. Vanura, B.R. Blazar, J.E. Karp, L. Luznik, I. Gojo, Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy, JCI Insight 3(21) (2018).
[20]
S. Tettamanti, A. Pievani, A. Biondi, G. Dotti, M. Serafini, Catch me if you can: how AML and its niche escape immunotherapy, Leukemia 36(1) (2022) 13-22.
Index Terms
- High expression of APOBEC3G predicts unfavorable prognosis and immune infiltration in patients with acute myeloid leukemia
Recommendations
Bipartite network analysis reveals metabolic gene expression profiles that are highly associated with the clinical outcomes of acute myeloid leukemia
Display Omitted Metabolic genes are as important prognostic biomarkers as oncogenes.We found that significant differences exist in metabolic processes of AML patients.We identified 62 metabolic genes that highly associated with the prognosis of ...
Prognostic Significance and Functional Implications of PPP1R12B in Acute Myeloid Leukemia
ICBBT '24: Proceedings of the 2024 16th International Conference on Bioinformatics and Biomedical TechnologyAcute Myeloid Leukemia (AML) is a life-threatening hematologic malignancy characterized by rapid proliferation of abnormal myeloid cells. This study employs comprehensive bioinformatics analyses to elucidate the role of the PPP1R12B gene, a member of the ...
Deep learning in molecular biology marker recognition of patients with acute myeloid leukemia
AbstractIn this study, the deep belief network (DBN) algorithm was used to identify the Wilm’s tumor 1 (WT1) gene expression levels, and then, the role of WT1 expression in the classification of acute myeloid leukemia (AML) was explored. 121 AML patients ...
Comments
Information & Contributors
Information
Published In
May 2023
313 pages
ISBN:9798400700385
DOI:10.1145/3608164
Copyright © 2023 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 07 November 2023
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Funding Sources
- Key scientific research plan projects of Shaanxi Education Department
- Scientific research plan projects of Shaanxi Education Department
- Natural Science Foundation of Shaanxi Province
Conference
ICBBT 2023
ICBBT 2023: 2023 15th International Conference on Bioinformatics and Biomedical Technology
May 26 - 28, 2023
Xi'an, China
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 22Total Downloads
- Downloads (Last 12 months)16
- Downloads (Last 6 weeks)2
Reflects downloads up to 02 Mar 2025
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format